# Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma

## TL;DR

This review discusses new treatment strategies for gliomas, focusing on a novel TMZ derivative that may overcome resistance issues in MGMT promoter-methylated gliomas.

## Contribution

The paper introduces KL-50, a new TMZ derivative that overcomes resistance in MGMT promoter-methylated gliomas via a novel DNA-modifying mechanism.

## Key findings

- KL-50 induces DNA interstrand crosslinks in the absence of MGMT, overcoming resistance to TMZ.
- MGMT promoter methylation is a key biomarker for response to alkylating agents like TMZ in gliomas.
- Mismatch repair loss is a resistance mechanism in gliomas treated with TMZ, but KL-50 shows potential to bypass this.

## Abstract

Adult diffuse gliomas are primary brain tumors notorious for leading to devastating neurologic consequences from both tumor progression and therapeutic interventions. The arsenal of current established treatments primarily includes surgery, radiotherapy, and DNA alkylating chemotherapy agents. Unfortunately, even with aggressive treatments, long-term cure is typically not attainable, except in certain cases of low-grade gliomas amenable to complete surgical resection. Grade 4 glioblastoma (GBM) represents the most aggressive and most common type of glioma in adults, is often resistant to current therapies, and is associated with a median survival of approximately 15 months. While biomarker-based therapies for gliomas are limited, O6-methylguanine-DNA methyltransferase (MGMT) is one well-established prognostic marker in GBM and is associated with improved response to the alkylating agent temozolomide (TMZ). Methylation of the MGMT promoter leading to loss of MGMT expression occurs in approximately half of GBMs and 70–80% of anaplastic and low-grade gliomas. While MGMT promoter-methylated gliomas are responsive to TMZ, a characteristic resistance mechanism of mismatch repair loss often emerges, resulting in recurrent drug-resistant disease. In prior work, we identified a new TMZ derivative “KL-50” which overcomes resistance to TMZ driven by loss of mismatch repair in preclinical glioma models. KL-50 functions via a novel DNA-modifying mechanism involving evolution of a primary alkyl lesion to a DNA interstrand crosslink specifically in the absence of MGMT. Research is ongoing to establish this new class of agents as a potential improved therapy in human gliomas. In this review, we provide an overview of the history and evolution of alkylator use in GBM, discuss the mechanisms and pitfalls of current therapies including toxicity or susceptibility to resistance mechanisms, and present the potential of a new wave of DNA modifiers to improve outcomes in gliomas.